Company* (Country; Symbol) |
Product |
Description |
Indication |
Status (Date) |
| | ||||
AUTOIMMUNE | ||||
Centocor Inc. (unit of Johnson & Johnson) |
Remicade |
Infliximab; anti-TNF antibody |
Fistulizing Crohn's disease |
Partner Schering-Plough Corp. received approval to market pro- duct in Europe for sustaining clinical response (10/23) |
|
||||
Millennium Pharmaceuticals Inc. (MLNM) |
MLN1202 |
Humanized monoclonal antibody designed to block MCP-1/CCR2 chemokine pathway |
Rheumatoid arthritis |
Company began a Phase II trial that will include about 30 patients; trial to be conducted in Europe and Australia (10/14) |
|
||||
ProMetic Life Sciences Inc. (Canada; TSE:PLI) and Arriva Pharmaceuticals Inc.* |
rAAT topical gel |
Recombinant alpha-1 antitrypsin |
Atopic dermatitis |
Companies' joint venture opened a Phase II proof-of-concept trial in Canada (10/9) |
|
||||
Revotar Biophar- maceuticals Inc.* (Germany; majority-owned subsidiary of Encysive Pharmaceuticals Inc.; ENCY) |
Bimosiamose |
Topical formulation of small-molecule selecting antagonist |
Psoriasis and atopic dermatitis |
Company started controlled Phase IIa trial in each indication (10/9) |
|
||||
CANCER | ||||
|
||||
Aphton Corp. (APHT) |
G17DT |
Anti-gastrin targeted immunotherapy |
Pancreatic cancer |
Results of Phase III trial in 154 patients in Europe showed increased survival in advanced patients for monotherapy arm vs. placebo (10/30) |
|
||||
Eximias Pharmaceutical Corp.* |
Thymitaq |
Thymidylate synthase inhibitor |
Hepatocellular carcinoma |
Eximias gained orphan designation for the product in Europe (10/9) |
|
||||
TopoTarget Prolifix A/S* (Denmark) |
PXD101 |
Histone deacetylase Inhibitor |
Advanced cancers |
TopoTarget started a Phase I trial in 24 to 36 patients at sites in the UK (10/13) |
|
||||
CARDIOVASCULAR | ||||
|
||||
Endovasc Inc. (OTC BB:EVSC) |
Liprostin |
Liposome formulation of prostaglandin E1 |
Critical limb ischemia and intermittent claudication |
Endovasc got approval in Republic of Georgia to begin clinical trials; other sites are in Brazil, Mexico and Eastern Europe (10/8) |
|
||||
CENTRAL NERVOUS SYSTEM | ||||
|
||||
Alkermes Inc. (ALKS) |
Risperdal Consta |
Long-acting injectable form of risperidone |
Schizophrenia |
Alkermes partner Janssen-Cilag SA gained approval in France (10/9) |
|
||||
Cephalon Inc. (CEPH) |
Vigil; Provigil |
Modafinil tablets |
Excessive daytime sleepiness |
Cephalon gained approval in Ger- many and Ireland (10/9) |
|
||||
|
Debiopharm SA* (Switzerland) |
ZT-1 |
Cholinesterase inhibitor |
Alzheimer's disease |
Company said it would start a Phase II trial in Europe in 180 patients with mild to moderate AD (10/20) |
|
||||
INFECTION | ||||
|
||||
Gilead Sciences Inc. (GILD) |
Emtriva (FDA-approved) |
Emtricitabine; nucleoside reverse transcriptase inhibitor |
HIV |
The European Union granted marketing approval in all 15 member states of the EU (10/28) |
|
||||
ID Biomedical Corp.* (Canada; IDBE) |
FluINsure |
Trivalent influenza vaccine for intranasal administration |
Influenza |
Company received approval in Canada for field trial in 1,320 healthy adults (10/16) |
|
||||
Ipsat Therapies Oy* (Finland) |
P1A |
Oral formulation designed to inactivate betalactam antibiotics |
Antibiotic-induced problems |
Company presented Phase I data showing successful removal of harmful antibiotic residue (10/13) |
|
||||
MedImmune Inc. (MEDI) and Abbott Laboratories |
Synagis (FDA-approved) |
Palivizumab; humanized monoclonal antibody |
Congenital heart disease |
Abbott gained approval in Europe to market drug for infants born with hemodynamically significant congenital heart disease (10/30) |
|
||||
MISCELLANEOUS | ||||
Abiogen Pharma SpA* (Italy) |
OGP |
Small sequence of osteogenic growth peptide |
Chronic idiopathic myelofibrosis |
EMEA granted orphan designation to the product (10/6) |
|
||||
Labopharm Inc.* (Canada) |
Tramadol |
Once-daily formulation of the analgesic |
Pain associated with osteoarthritis |
Data presented from European Phase III trial showed product provided equivalent efficacy to extended-release, twice-daily formulation (10/15) |
|
||||
Cangene Corp. (Canada; TSE:CNJ) |
Leucotropin |
GM-CSF protein |
To enhance white blood cells in those with Hodgkin's disease or non- Hodgkin's lymphoma after stem cell transplantation |
Cangene filed for approval in Canada (10/7) |
|
||||
Xcellentis (subsidiary of Innogentics NV; Belgium) |
LymphoDerm |
Agent in proprietary topical formulation |
Hard-to-treat venous leg ulcers |
Preliminary Phase II results in 195 patients studied in four countries showed a clear trend toward improvement vs. standard of care (10/28) |
|
||||
| | ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
